Canada Pension Plan Investment Board Has $17.12 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Canada Pension Plan Investment Board decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 160,400 shares of the specialty pharmaceutical company’s stock after selling 1,200 shares during the period. Canada Pension Plan Investment Board owned approximately 0.25% of Jazz Pharmaceuticals worth $17,119,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Janney Montgomery Scott LLC increased its holdings in shares of Jazz Pharmaceuticals by 48.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 10,949 shares of the specialty pharmaceutical company’s stock worth $1,347,000 after purchasing an additional 3,591 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $380,000. UBS Group AG increased its position in shares of Jazz Pharmaceuticals by 18.4% during the fourth quarter. UBS Group AG now owns 172,947 shares of the specialty pharmaceutical company’s stock valued at $21,272,000 after purchasing an additional 26,844 shares during the period. Coldstream Capital Management Inc. acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $227,000. Finally, Assetmark Inc. lifted its position in Jazz Pharmaceuticals by 37.1% in the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 119 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $108.99 on Tuesday. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The firm has a 50 day simple moving average of $110.90 and a 200 day simple moving average of $110.95. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $137.38. The firm has a market cap of $6.87 billion, a P/E ratio of 22.47, a P/E/G ratio of 1.31 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on JAZZ. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Piper Sandler lowered their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, UBS Group cut their price objective on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a report on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.